Ken Griffin Tempest Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Tempest Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 34,500 shares of TPST stock, worth $28,980. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,500
Previous 27,500
25.45%
Holding current value
$28,980
Previous $38,000
26.32%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TPST
# of Institutions
39Shares Held
6.35MCall Options Held
34.9KPut Options Held
148K-
Versant Venture Management, LLC San Francisco, CA3.51MShares$2.95 Million4.35% of portfolio
-
Black Rock Inc. New York, NY550KShares$462,2020.0% of portfolio
-
Jane Street Group, LLC New York, NY493KShares$414,1980.0% of portfolio
-
Geode Capital Management, LLC Boston, MA354KShares$297,5910.0% of portfolio
-
Ubs Group Ag196KShares$164,3670.0% of portfolio
About Tempest Therapeutics, Inc.
- Ticker TPST
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,418,900
- Market Cap $8.75M
- Description
- Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...